US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.33

-1.0900-8.78%

Post-market: 11.400.0700+0.62%19:30 EDT

Volume:299.63K

Turnover:3.40M

Market Cap:3.84B

PE:-536.97

High:11.39

Open:11.34

Low:11.19

Close:12.42

52wk High:12.60

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:2.20

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0211

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.88

PE(LYR):-536.97

Loading ...

Overview Company News Filings

Canaccord Genuity Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix underscores radiopharma portfolio and regulatory risks at shareholder meeting

Telix boosts radiopharma scale and pivots deeper into cancer therapeutics

Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial

MT Newswires Live

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches

MT Newswires Live

Telix announces LoI to collaborate with EDAP TMS and Profound Medical

New Kidney and Brain Imaging Data Might Change The Case For Investing In Telix (ASX:TLX)

Simply Wall St.

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG) and Telix Pharmaceuticals (OtherTLPPF)

Telix Issues New Shares to Complete Deferred ImaginAb Acquisition Payment

Challenger exits substantial holding in Telix Pharmaceuticals

Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares

Simply Wall St.

Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?

Simply Wall St.

TLX101-Px (Pixlumi®) MAA Accepted in Europe

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration

Simply Wall St.

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

Telix to Release Escrowed Shares from Lightpoint Acquisition

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/TLX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":11.33,"timestamp":1787342400000,"preClose":12.42,"halted":0,"volume":299625,"hourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"delay":0,"changeRate":-0.08776167471819644,"floatShares":272000000,"shares":339000000,"eps":-0.0211,"marketStatus":"Market Closed","change":-1.09,"latestTime":"08-21 16:00:00 EDT","open":11.34,"high":11.39,"low":11.19,"amount":3395453.5710000005,"amplitude":0.016103,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":12.42,"preHourTrading":{"tag":"盘前","latestPrice":11.3,"preClose":12.42,"latestTime":"09:29 EDT","volume":9930,"amount":113052.21588,"timestamp":1787318999999,"change":-1.12,"changeRate":-0.090177,"amplitude":0.02818},"postHourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"volumeRatio":2.1988469508579978},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":2.1988469508579978,"shares":339000000,"dividePrice":0,"high":11.39,"amplitude":0.016103,"preClose":12.42,"low":11.19,"week52Low":6.28,"pbRate":"7.88","psRate":"4.31","week52High":12.5999,"institutionHeld":0,"latestPrice":11.33,"eps":-0.0211,"divideRate":0,"volume":299625,"delay":0,"ttmEps":-0.0211,"open":11.34,"prevYearClose":7.49,"prevWeekClose":11.82,"prevMonthClose":9.89,"prevQuarterClose":11.53,"fiveDayClose":11.82,"twentyDayClose":10.22,"sixtyDayClose":9.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-08-21","current":-536.966825,"percent":0.281179,"low":-584.49693,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"high":383.853933,"avg":21.978205,"sd":314.696392,"marketCap":3778875522.96},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96}],"updateTime":1787436004078},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638563652","title":"Canaccord Genuity Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638563652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638563652?lang=en_us&edition=fundamental","pubTime":"2026-05-26 07:40","pubTimestamp":1779752408,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$30.00. Storey covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637322243","title":"Telix underscores radiopharma portfolio and regulatory risks at shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637322243","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637322243?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:33","pubTimestamp":1779374025,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals used its latest shareholder meeting materials to hig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-underscores-radiopharma-portfolio-and-regulatory-risks-at-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-underscores-radiopharma-portfolio-and-regulatory-risks-at-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4544","TLX","BK4139","ARKG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637332210","title":"Telix boosts radiopharma scale and pivots deeper into cancer therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2637332210","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637332210?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:33","pubTimestamp":1779374008,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix used its 2025 Annual General Meeting to highlight strong commercial moment...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-boosts-radiopharma-scale-and-pivots-deeper-into-cancer-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-boosts-radiopharma-scale-and-pivots-deeper-into-cancer-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636500265","title":"Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636500265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636500265?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:52","pubTimestamp":1779144775,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  has completed patient enrolment in the IPAX-2 study evaluating TLX101-Tx in newly diagnosed glioblastoma, with the company reporting no dose-limiting toxicities observed to date, according to a Tuesday statement.The study is a dose-finding trial evaluating TLX101-Tx in combination with standard post-surgical radiotherapy and temozolomide, and it will proceed with follow-up to establish the maximum tolerated dose.Twelve patients were enrolled in three dose-escalation cohorts across four sites in Australia, Austria, and the Netherlands to assess safety, tolerability, and determine the maximum tolerated dose.TLX101-Tx is also being evaluated in the ongoing pivotal phase three IPAX BrIGHT trial for recurrent glioblastoma, which is currently enrolling patients across multiple countries.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","BK7067","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636001489","title":"IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636001489","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636001489?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:00","pubTimestamp":1779138000,"startTime":"0","endTime":"0","summary":"IPAX-2 study of TLX101-Tx (I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, wh","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3297047/0/en/IPAX-2-Study-of-TLX101-Tx-in-First-line-Glioblastoma-Completes-Enrolment-and-Confirms-Dosing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","MTD","BK4585","BK4548","IE00BYQQ9H92.USD","LU0347712357.USD","IE00B5TLWC47.USD","LU1721428933.USD","ASX","TLX","BK4567","BK4121","LU2211817866.USD","BK4141","BK4588","LU2413666426.HKD","IE00BFXG0V08.USD","BK4526","BK4543","BK4139","LU1093756168.USD","LU1093756325.SGD","LU2413666699.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046412","title":"Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046412","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636046412?lang=en_us&edition=fundamental","pubTime":"2026-05-18 11:57","pubTimestamp":1779076630,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  shares fell 3% in recent Monday trade after the company said late Friday it has entered into letters of intent to pursue collaborations with EDAP TMS and Profound Medical, developers of minimally invasive and image-guided ablative treatment technologies for prostate cancer.The company said in a statement that the collaborations will explore the investigational use of its prostate-specific membrane antigen positron emission tomography imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound and other image-guided therapies designed to treat localized prostate cancer, including transurethral ultrasound ablation.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635855630","title":"Telix announces LoI to collaborate with EDAP TMS and Profound Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2635855630","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635855630?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:40","pubTimestamp":1778841651,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with EDAP TMS (EDAP) and Profoun...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telix-announces-loi-to-collaborate-with-edap-tms-and-profound-medical-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telix-announces-loi-to-collaborate-with-edap-tms-and-profound-medical-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EDAP","BK4082","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635774067","title":"New Kidney and Brain Imaging Data Might Change The Case For Investing In Telix (ASX:TLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635774067","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635774067?lang=en_us&edition=fundamental","pubTime":"2026-05-15 11:38","pubTimestamp":1778816299,"startTime":"0","endTime":"0","summary":"In early May 2026, Telix Pharmaceuticals reported new independent Phase 3 ZIRCON analyses in European Urology showing TLX250-Px PET/CT may predict malignancy across a broad range of renal cancer subtypes, alongside progress of its glioma imaging candidate TLX101-Px with a validated European marketing authorization application now under active review.\nThese updates highlight how Telix’s radiopharmaceutical imaging portfolio could extend beyond clear cell kidney cancer into non-clear cell...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/new-kidney-and-brain-imaging-data-might-change-the-case-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/new-kidney-and-brain-imaging-data-might-change-the-case-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","BK7067","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635076495","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076495","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635076495?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:45","pubTimestamp":1778723107,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after the FDA accepted its resubmitted New Drug Application for brain imaging agent Pixclara and the company reaffirmed its FY2026 revenue guidance alongside several late stage pipeline updates.\nSee our latest analysis for Telix Pharmaceuticals.\nAt A$14.52, Telix’s stock has given investors a 59.91% 90 day share price return and a 27.82% year to date share price return, yet the 1 year total shareholder return is down 43.19%, so near term...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","LABU","BK4585","TLX.AU","BK4139","BK4588","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633107996","title":"Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG) and Telix Pharmaceuticals (OtherTLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633107996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633107996?lang=en_us&edition=fundamental","pubTime":"2026-05-08 10:10","pubTimestamp":1778206209,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 10x Genomics (TXG) and Telix Pharmaceuticals (TLPP...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-10x-genomics-txg-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-10x-genomics-txg-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4137","HCSG","LU0128526141.USD","BK4548","LU1861558580.USD","LU1861559042.SGD","XBI","BK4585","XLV","TXG","BK4588","BK4121","LU0029874061.USD","BK4139","TLX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633041771","title":"Telix Issues New Shares to Complete Deferred ImaginAb Acquisition Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2633041771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633041771?lang=en_us&edition=fundamental","pubTime":"2026-05-08 09:21","pubTimestamp":1778203272,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals has issued 264,943 fully paid ordinary shares to satisfy a US$4 mil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-shares-to-complete-deferred-imaginab-acquisition-payment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-shares-to-complete-deferred-imaginab-acquisition-payment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633312901","title":"Challenger exits substantial holding in Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2633312901","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633312901?lang=en_us&edition=fundamental","pubTime":"2026-05-06 14:54","pubTimestamp":1778050447,"startTime":"0","endTime":"0","summary":"Challenger ( ($AU:CGF) ) has provided an update. Challenger Limited has notified the ASX that it and its associated entities have ceased to be subs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/challenger-exits-substantial-holding-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/challenger-exits-substantial-holding-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633676769","title":"Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633676769","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633676769?lang=en_us&edition=fundamental","pubTime":"2026-05-05 07:37","pubTimestamp":1777937833,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals yesterday and set a price target of A$30.00. Storey covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX","TLPPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633677961","title":"New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2633677961","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633677961?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:00","pubTimestamp":1777928400,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, May  05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287198/0/en/New-Publication-Demonstrates-TLX250-Px-Zircaix-Potential-in-Diagnosing-Kidney-Cancers-Beyond-ccRCC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4543","SOC","BK4213","TLX","ASX","BK4141","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632705906","title":"Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632705906","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632705906?lang=en_us&edition=fundamental","pubTime":"2026-05-03 06:02","pubTimestamp":1777759366,"startTime":"0","endTime":"0","summary":"Those following along with Telix Pharmaceuticals Limited ( ASX:TLX ) will no doubt be intrigued by the recent purchase...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/insider-buying-telix-pharmaceuticals-co-founder-bought-us997","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/insider-buying-telix-pharmaceuticals-co-founder-bought-us997","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623733","title":"Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623733","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623733?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:45","pubTimestamp":1777668303,"startTime":"0","endTime":"0","summary":"In late April 2026, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA dosimetry data for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in non-target organs and supporting further evaluation in earlier-stage disease, while also progressing a Regeneron collaboration and a European review of its glioma imaging agent TLX101-Px.\nThese developments highlight how Telix is trying to build an integrated radiopharmaceutical platform, pairing next-generation...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-new-tlx597-tx-data-and-pipeline-progression-change-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-new-tlx597-tx-data-and-pipeline-progression-change-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632629956","title":"TLX101-Px (Pixlumi®) MAA Accepted in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2632629956","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632629956?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:43","pubTimestamp":1777585380,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, May  01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285581/0/en/TLX101-Px-Pixlumi-MAA-Accepted-in-Europe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","BK4526","BK4585","BK4141","BK4543","TLX","MAA","BK4139","BK4588","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631527403","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527403","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631527403?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:09","pubTimestamp":1777496942,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has drawn fresh attention after announcing plans to showcase OPTIMAL-PSMA 2 data on its TLX597-Tx candidate, alongside upcoming TLX591-Tx trial results and a new collaboration with Regeneron Pharmaceuticals.\nSee our latest analysis for Telix Pharmaceuticals.\nThese clinical updates and the Regeneron partnership arrive during a period of strong share price momentum, with Telix recording a 15.03% 1 month share price return and a 35.38% 3 month share price return,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-new-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631245605","title":"OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2631245605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631245605?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:00","pubTimestamp":1777496400,"startTime":"0","endTime":"0","summary":"TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.OPTIMAL-PSMA2 initial dosimetry dat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284336/0/en/OPTIMAL-PSMA-Trial-of-TLX597-Tx-Next-Generation-RLT-Presented-at-IPCS-2026-Highlighting-Therapeutic-Potential-in-Prostate-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","BK4141","BK4139","TLX","BK4543","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631676285","title":"Telix to Release Escrowed Shares from Lightpoint Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2631676285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631676285?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:08","pubTimestamp":1777450090,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an update. Telix Pharmaceuticals has announced that 45,584 ordinary shares issued to Lightpoint M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-to-release-escrowed-shares-from-lightpoint-acquisition-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-to-release-escrowed-shares-from-lightpoint-acquisition-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":199,"code":"91000000","status":"200"}]}}